Evotec (ETR:EVT) Share Price Crosses Above Fifty Day Moving Average – What’s Next?

Evotec SE (ETR:EVT)’s share price passed above its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of €2.96 and traded as high as €2.97. Evotec shares last traded at €2.97, with a volume of 1,111,092 shares traded.

Evotec Stock Performance

The company has a market cap of $543.65 million, a price-to-earnings ratio of -3.17, a price-to-earnings-growth ratio of 0.98 and a beta of 1.27. The company has a debt-to-equity ratio of 71.50, a current ratio of 2.33 and a quick ratio of 2.97. The stock has a 50-day moving average price of €2.96 and a 200 day moving average price of €4.44.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic.